Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses

PLoS Pathogens

Volumn 10, Issue 5, 2014, Pages

  Avnir, Yuval ^a   Tallarico, Aimee S ^a   Zhu, Quan ^a   Bennett, Andrew S ^a   Connelly, Gene ^a   Sheehan, Jared ^a   Sui, Jianhua ^a   Fahmy, Amr ^a   Huang, Chiung yu ^b,e   Cadwell, Greg ^c   Bankston, Laurie A ^c   McGuire, Andrew T ^d   Stamatatos, Leonidas ^d   Wagner, Gerhard ^a   Liddington, Robert C ^c   Marasco, Wayne A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c BURNHAM INSTITUTE   (United States)

^d SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CHEMICAL STRUCTURE; CHEMISTRY; EPITOPE MAPPING; GENETICS; HEMAGGLUTINATION; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A; METABOLISM; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROTEIN ENGINEERING; PROTEIN QUATERNARY STRUCTURE; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODIES, NEUTRALIZING; EPITOPE MAPPING; EPITOPES; HEMAGGLUTINATION, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROTEIN ENGINEERING; PROTEIN STRUCTURE, QUATERNARY; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84901687604     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004103     Document Type: Article

References (55)

1. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
2. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105: 5986-5991.
3. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
4. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
5. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, et al. (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843-850.
6. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
7. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
8. Nakamura G, Chai N, Park S, Chiang N, Lin Z, et al. (2013) An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14: 93-103.
9. Friesen RH, Lee PS, Stoop EJ, Hoffman RM, Ekiert DC, et al. (2014) A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A 111: 445-450.
10. Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120: 1663-1673.
11. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193.
12. Thomson CA, Wang Y, Jackson LM, Olson M, Wang W, et al. (2012) Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front Immunol 3: 87.
13. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, et al. (2012) Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 109: 9047-9052.
14. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, et al. (2011) Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis 52: 1003-1009.
15. Pica N, Hai R, Krammer F, Wang TT, Maamary J, et al. (2012) Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A 109: 2573-2578.
16. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, et al. (2013) 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 207: 98-105.
17. Boyd SD, Gaeta BA, Jackson KJ, Fire AZ, Marshall EL, et al. (2010) Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. J Immunol 184: 6986-6992.
18. Glanville J, Kuo TC, von Budingen HC, Guey L, Berka J, et al. (2011) Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation. Proc Natl Acad Sci U S A 108: 20066-20071.
19. Schroeder HW Jr, Hillson JL, Perlmutter RM, (1987) Early restriction of the human antibody repertoire. Science 238: 791-793.
20. Sasso EH, Willems van Dijk K, Bull AP, Milner EC, (1993) A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles. J Clin Invest 91: 2358-2367.
21. Milner EC, Hufnagle WO, Glas AM, Suzuki I, Alexander C, (1995) Polymorphism and utilization of human VH Genes. Ann N Y Acad Sci 764: 50-61.
22. Harris AK, Meyerson JR, Matsuoka Y, Kuybeda O, Moran A, et al. (2013) Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A 110: 4592-4597.
23. Victora GD, Nussenzweig MC, (2012) Germinal centers. Annu Rev Immunol 30: 429-457.
24. Cerutti A, Cols M, Puga I, (2013) Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 13: 118-132.
25. Meireles LM, Domling AS, Camacho CJ, (2010) ANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery. Nucleic Acids Res 38: W407-411.
26. Lingwood D, McTamney PM, Yassine HM, Whittle JR, Guo X, et al. (2012) Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489: 566-570.
27. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593-1602.
28. Peled JU, Kuang FL, Iglesias-Ussel MD, Roa S, Kalis SL, et al. (2008) The biochemistry of somatic hypermutation. Annu Rev Immunol 26: 481-511.
29. Rogozin IB, Pavlov YI, Bebenek K, Matsuda T, Kunkel TA, (2001) Somatic mutation hotspots correlate with DNA polymerase eta error spectrum. Nat Immunol 2: 530-536.
30. Clark LA, Ganesan S, Papp S, van Vlijmen HW, (2006) Trends in antibody sequence changes during the somatic hypermutation process. J Immunol 177: 333-340.
31. Almagro JC, Beavers MP, Hernandez-Guzman F, Maier J, Shaulsky J, et al. (2011) Antibody modeling assessment. Proteins 79: 3050-3066.
32. Corti D, Lanzavecchia A, (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31: 705-742.
33. Sasso EH, Johnson T, Kipps TJ, (1996) Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest 97: 2074-2080.
34. Han T, Marasco WA, (2011) Structural basis of influenza virus neutralization. Ann N Y Acad Sci 1217: 178-190.
35. Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, et al. (2007) Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 179: 5886-5896.
36. Vinuesa CG, Linterman MA, Goodnow CC, Randall KL, (2010) T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 237: 72-89.
37. Schwickert TA, Victora GD, Fooksman DR, Kamphorst AO, Mugnier MR, et al. (2011) A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J Exp Med 208: 1243-1252.
38. Puga I, Cols M, Barra CM, He B, Cassis L, et al. (2012) B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol 13: 170-180.
39. Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, et al. (2013) The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol 14: 1266-1276.
40. Wei CJ, Yassine HM, McTamney PM, Gall JG, Whittle JR, et al. (2012) Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci Transl Med 4: 147ra114.
41. Goff PH, Eggink D, Seibert CW, Hai R, Martinez-Gil L, et al. (2013) Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8: e79194.
42. Eggink D, Goff PH, Palese P, (2014) Guiding the Immune Response against Influenza Virus Hemagglutinin toward the Conserved Stalk Domain by Hyperglycosylation of the Globular Head Domain. J Virol 88: 699-704.
43. Krammer F, Palese P, (2013) Universal influenza virus vaccines: need for clinical trials. Nat Immunol 15: 3-5.
44. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, et al. (2013) Rational HIV immunogen design to target specific germline B cell receptors. Science 340: 711-716.
45. Krammer F, Pica N, Hai R, Margine I, Palese P, (2013) Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87: 6542-6550.
46. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, et al. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1: e00018-10.
47. Bommakanti G, Lu X, Citron MP, Najar TA, Heidecker GJ, et al. (2012) Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 86: 13434-13444.
48. Lu Y, Welsh JP, Swartz JR, (2014) Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci U S A 111: 125-130.
49. Potter KN, Li Y, Mageed RA, Jefferis R, Capra JD, (1999) Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8. Scand J Immunol 50: 14-20.
50. Finn JA, Crowe JE Jr, (2013) Impact of new sequencing technologies on studies of the human B cell repertoire. Curr Opin Immunol 25: 613-618.
51. Watson CT, Steinberg KM, Huddleston J, Warren RL, Malig M, et al. (2013) Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation. Am J Hum Genet 92: 530-546.
52. Studier FW, (2005) Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 41: 207-234.
53. Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, et al. (2013) Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs. PLoS Pathog 9: e1003106.
54. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
55. Fahmy A, Wagner G, (2011) Optimization of van der Waals energy for protein side-chain placement and design. Biophys J 101: 1690-1698.